Valo Tx Logo.jpg
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
11 janv. 2023 02h00 HE | Valo Therapeutics LTD
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it...
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies -Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and...
Global Head And Neck Cancer Therapeutics Market Report 2022: Featuring Eli Lilly, Merck, Sanofi, Takeda Pharmaceutical & More
09 janv. 2023 07h48 HE | Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "Global Head And Neck Cancer Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy Type (Immunotherapy, Chemotherapy, and...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
06 janv. 2023 14h50 HE | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Global Cellular Immunotherapy Market
Cellular Immunotherapy (CAR T Cell Therapy, Dendritic Cell Therapy) Market Trends/Analysis Report 2022
06 janv. 2023 06h03 HE | Research and Markets
Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Cellular Immunotherapy Market Size, Share & Trends Analysis Report by Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy), by...
Global Nasopharyngeal Cancer Market Report 2022 to 2028: Dramatic Rise in the Prevalence Rate of Nasopharyngeal Cancer Owing to the Excessive Consumption of Tobacco and Alcohol Drives Growth
05 janv. 2023 07h18 HE | Research and Markets
Dublin, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The "Global Nasopharyngeal Cancer Market Research and Forecast, 2022-2028" report has been added to's offering. The global market...
PDS Biotech Logo.png
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
03 janv. 2023 07h00 HE | PDS Biotechnology Corporation
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform PDS Biotech to host conference call and webcast on Tuesday, January 3, 2023, at...
Cancer Immunotherapy Global Market Report 2022: Spike in R&D Efforts for the Creation of Novel Oncology Treatment Bolsters 7.5% Annual Growth
29 déc. 2022 06h13 HE | Research and Markets
Dublin, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market by Product, Distribution Channel, Application, End Use, and by Region - Global Forecast to 2022-2033" report has been added...
PDS Biotech Logo.png
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months
28 déc. 2022 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 28, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Affimed Logo.jpg
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
22 déc. 2022 06h30 HE | Affimed N.V.
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of...